Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Netflix's 'Lord of the Flies' show blends 'Adolescence' and 'Yellowjackets' - 2The Benefits of Rehearsing Careful Nurturing
- 3Support Your Body: A Manual for Smart dieting and Sustenance
- 4Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- 5EU foreign ministers commemorate Russian massacre in Bucha
- The Way to Business: Startup Illustrations Learned
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
- From Loner to Force to be reckoned with: Individual Accounts of Change
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- Hundreds of Gazans evacuated from Strip for medical treatment - COGAT
- First Houthi launch toward Israel since war began triggers alerts across the Negev
- This Week In Space podcast: Episode 186 — Snow on the Moon?
- Artemis II updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
